SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are heavily focused on political affiliations following a shooting involving Charlie Kirk, with community members debating the shooter's motives and ideological alignment. Some users are pointing fingers between the left and right, while others are highlighting the broader implications of political rhetoric and violence. The stock is also being discussed in relation to broader market trends and potential financial impacts.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending downwards as reports circulate that the Trump administration may link COVID-19 vaccines to child deaths, creating uncertainty around the stock's future. The community is discussing the potential impact of this news, while some investors see a buying opportunity due to the perceived overreaction and low valuation. Discussions also include Moderna's pipeline beyond COVID-19, especially its personalized cancer vaccine program.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock experiences a notable surge, prompting discussions about potential catalysts and future price movements. Community members are debating the sustainability of the rally, with some pointing to technical breakouts and potential for higher prices, while others express skepticism, citing concerns about valuation and market conditions. Elon Musk's recent activities and their potential impact on the company are also being discussed.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN.X) is trending amidst discussions about potential pumps and dumps, with community members analyzing buying patterns and anticipating price movements. Some investors express optimism based on the upcoming Goliath Testnet deployment and potential for an altseason, while others remain skeptical, citing concerns about manipulation and past performance. Discussions also revolve around the Onyx Wallet release, Chain's involvement, and the project's alignment with institutional finance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Equity

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of gene therapy developer uniQure N.V. (QURE) shot up 41% on Thursday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">announced</a> that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its AMT-130 gene therapy for the treatment of Huntington’s disease.The new designation is in addition to the existing Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations granted to AMT-130.uniQure CEO Walid Abi-Saab said that the designation underscores both the urgent need for effective treatments for Huntington’s disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression.He added that the company looks to commercialize the drug as quickly as possible.Forty-five patients have received AMT-130 to date as part of trials, the company stated, while adding that an additional regulatory update regarding its Biologics License Application submission to the FDA requesting marketing approval is expected in the second quarter.Huntington’s disease is a rare, inherited neurodegenerative disorder. According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington’s disease in the U.S. and Europe, with hundreds of thousands of others at risk of inheriting it.FDA’s Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates that are intended to treat a serious condition, and if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.On Stocktwits, retail sentiment around uniQure flipped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1292/302;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_12_38_37_PM_png_86c013b014.webp" alt="QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits" width="1292" height="302"><figcaption>QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down approximately 27% year-to-date but up about 183% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spirit-airlines-appoints-dave-davis-as-ceo/chQEDnoRbfA">Spirit Airlines Appoints Dave Davis As CEO After Emerging From Bankruptcy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B CSL Behring's Gene...

Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels since mid-June 2023.The surge came after uniQure announced it had reached an agreement with the U.S. Food and Drug Administration (FDA) on key aspects of an Accelerated Approval pathway for its AMT-130 treatment, a potential therapy for Huntington’s disease.&nbsp;This agreement means data from the ongoing Phase I/II studies, compared to an external control, could serve as the primary basis for a biologics license application (BLA) submission without requiring an additional pre-submission study.uniQure’s AMT-130 previously received a regenerative medicine advanced therapy (RMAT) designation from the FDA in May, underscoring its potential to address unmet medical needs in Huntington’s disease.&nbsp;Analysts have viewed this development as a major milestone.Cantor Fitzgerald analyst Kristen Kluska raised her price target for uniQure to $58 from $28 and maintained an ‘Overweight’ rating, noting that the FDA’s approval signals potential pharma interest given the clearer path toward market entry.Stifel also weighed in, describing the development as “a best-case scenario” and noting that uniQure can use external controls and data from ongoing studies.&nbsp;Stifel has a ‘Buy’ rating and predicts the FDA agreement will bolster confidence in uniQure’s pipeline, despite the low initial expectations for this accelerated pathway.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QURE_sentiment_and_message_volume_Dec_10_premarket_98c55fcc19.png" alt="QURE sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>QURE sentiment and message volume Dec 10 premarket as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’, with QURE trending among the top 10 tickers late Tuesday morning.<stembedurl>https://stocktwits.com/nbkihy8/message/595867060</stembedurl><stembedurl>https://stocktwits.com/DaBeavzz65/message/578931944</stembedurl>uniQure’s stock has more than doubled in value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Neurons in dementia, conceptual illustration - stock illustration

uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QURE uniQure N.V.